Prem Sethi, a promoter of Entero Healthcare Solutions Limited , has declared that no encumbrance was created on the company's shares during the financial year ended March 31, 2026. The disclosure, submitted to the stock exchanges, confirms that neither Sethi nor persons acting in concert with him established any direct or indirect charges on the shares throughout FY26.

The declaration was made in compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This regulation requires promoters to annually disclose any encumbrance on their holdings to ensure transparency for shareholders.

The filing was addressed to BSE Limited and the National Stock Exchange of India Limited on April 06, 2026. A copy of the declaration was also marked to the Chairperson of the Audit Committee of Entero Healthcare Solutions Limited.

Key Filing Details

The document confirms that the promoter's shareholding remains free from pledges or other charges for the reported period.

Entero Healthcare Solutions Limited reported a 36% year-on-year increase in profit after tax (PAT) to ₹146 crore for the financial year ended March 31, 2026, driven by robust operational performance and strategic acquisitions. Revenue from operations for FY26 grew by 31.5% on a like-for-like basis to ₹6,591 crore, while EBITDA improved to ₹266 crore with a margin expansion of 67 basis points to 4%. The company’s operating cash flow for the year stood at ₹96.2 crore, a significant turnaround from the previous year. The company released the transcript of the earnings call held on May 26, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Q4 & FY26 Financial Highlights

Entero Healthcare delivered significant improvement across key financial metrics during the quarter and full year. The consolidated net profit for Q4FY26 stood at ₹45.1 crore, compared to the corresponding period of the previous year. EBITDA for the quarter increased to ₹86 crore, with the EBITDA margin expanding to 4.5%.

For the full year FY26, revenue grew by 31.5% to ₹6,591 crore. The company achieved an EBITDA margin of 4%, up from 3.33% in FY25, and reported a net profit after tax of ₹146 crore. The operating cash flow for FY26 was recorded at ₹96.2 crore.

Operational and Strategic Updates

The company outperformed market growth, recording an organic growth of 15.6% against the industry IPM growth of 10% in FY26. Entero expanded its operational reach, covering 523 districts and serving over 100,000 retail customers. The company completed seven acquisitions during the year, including Sai RK Pharma Pvt Ltd and Ace Cardiopathy Solutions Pvt Ltd, to strengthen its presence in specialty pharma and MedTech segments. The MedTech segment now contributes more than ₹1,000 crore in annualized revenue.

FY27 Guidance and Outlook

Management provided guidance for FY27, targeting consolidated revenue growth of 23% year-on-year, excluding any new acquisitions. The company aims to achieve an EBITDA margin of 5%, driven by profitable revenue growth and operational efficiencies. Entero intends to maintain an EBITDA to operating cash flow conversion ratio of at least 50%. The MedTech segment is expected to contribute more than 15% to revenue, with potential to reach 20% in 2-3 years. The company expects the tax rate to be in the range of 22%-23% for FY27.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE010601016/d7bae6c07be64939.pdf